Xiaoling Cheng

995 total citations
74 papers, 733 citations indexed

About

Xiaoling Cheng is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaoling Cheng has authored 74 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Xiaoling Cheng's work include Platelet Disorders and Treatments (26 papers), Blood groups and transfusion (15 papers) and Hemophilia Treatment and Research (13 papers). Xiaoling Cheng is often cited by papers focused on Platelet Disorders and Treatments (26 papers), Blood groups and transfusion (15 papers) and Hemophilia Treatment and Research (13 papers). Xiaoling Cheng collaborates with scholars based in China, Canada and United States. Xiaoling Cheng's co-authors include Hongyuan Yan, Ning Sun, Gengliang Yang, James A. Ruth, Runhui Wu, Zhenping Chen, Hongbo Le, Qin Luo, Jianguo He and Xiaoqiang Qiao and has published in prestigious journals such as Analytical Chemistry, Journal of Agricultural and Food Chemistry and Food Chemistry.

In The Last Decade

Xiaoling Cheng

60 papers receiving 725 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoling Cheng China 14 228 125 116 114 100 74 733
Oliver Scherf‐Clavel Germany 16 58 0.3× 94 0.8× 80 0.7× 89 0.8× 176 1.8× 61 771
Manuel David Peris‐Díaz Poland 13 62 0.3× 38 0.3× 83 0.7× 93 0.8× 282 2.8× 30 753
Bart Hens Belgium 20 170 0.7× 14 0.1× 59 0.5× 40 0.4× 183 1.8× 44 1.2k
Uwe Thuß Germany 10 74 0.3× 138 1.1× 91 0.8× 26 0.2× 127 1.3× 15 547
Jean‐Paul Cano France 18 77 0.3× 59 0.5× 27 0.2× 65 0.6× 242 2.4× 39 919
J. D. Kruse-Jarres Germany 11 243 1.1× 38 0.3× 159 1.4× 15 0.1× 139 1.4× 44 801
Bonnie Mei-Wah Fong China 15 39 0.2× 51 0.4× 138 1.2× 26 0.2× 424 4.2× 21 879
Nelci F. Höehr Brazil 18 74 0.3× 49 0.4× 53 0.5× 19 0.2× 171 1.7× 35 828
Xiaowen Yan China 19 154 0.7× 16 0.1× 99 0.9× 38 0.3× 491 4.9× 51 1.1k
Alan Knapton United States 20 22 0.1× 53 0.4× 152 1.3× 83 0.7× 364 3.6× 39 1.1k

Countries citing papers authored by Xiaoling Cheng

Since Specialization
Citations

This map shows the geographic impact of Xiaoling Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Cheng more than expected).

Fields of papers citing papers by Xiaoling Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoling Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Cheng. The network helps show where Xiaoling Cheng may publish in the future.

Co-authorship network of co-authors of Xiaoling Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoling Cheng. A scholar is included among the top collaborators of Xiaoling Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoling Cheng. Xiaoling Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Huang, Weiting, et al.. (2024). Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy. Toxicology and Applied Pharmacology. 491. 117066–117066. 2 indexed citations
4.
Chen, Zhenping, Guoqing Liu, Gang Li, et al.. (2024). Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center. Pediatric Investigation. 8(4). 244–252.
5.
Wang, Zhifa, et al.. (2024). The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China. British Journal of Haematology. 205(1). 300–305. 1 indexed citations
6.
Wang, Zhifa, Aijun Zhang, Nan Wang, et al.. (2024). Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. British Journal of Haematology. 204(5). 1958–1965. 5 indexed citations
7.
Wang, Zhifa, et al.. (2024). Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring. British Journal of Haematology. 205(5). 1930–1937. 2 indexed citations
8.
Wang, Zhifa, et al.. (2023). Transient increase in platelet counts associated with COVID‐19 infection during TPO‐RA as the second‐line treatment in children with ITP. British Journal of Haematology. 203(3). 384–388. 2 indexed citations
9.
Wang, Zhifa, Nan Wang, Jingjing Liu, et al.. (2023). Long‐term eltrombopag in children with chronic immune thrombocytopenia: A single‐centre extended real‐life observational study in China. British Journal of Haematology. 204(3). 1017–1023. 3 indexed citations
10.
Li, Zekun, Zhenping Chen, Guoqing Liu, et al.. (2023). Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes. Thrombosis Research. 225. 33–38. 5 indexed citations
11.
Wang, Zhifa, Lijuan Wang, Yan Liu, et al.. (2023). Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. British Journal of Haematology. 202(2). 422–428. 9 indexed citations
12.
Cheng, Xiaoling, et al.. (2023). Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real‐world study in China. British Journal of Haematology. 202(3). 636–644. 8 indexed citations
13.
Cheng, Xiaoling, et al.. (2022). Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study. Expert Review of Clinical Pharmacology. 15(3). 365–369. 1 indexed citations
14.
Li, Zekun, Guoqing Liu, Zhenping Chen, et al.. (2022). Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China. Haemophilia. 28(4). 625–632. 3 indexed citations
15.
Cheng, Xiaoling, Lingling Fu, Zhenping Chen, et al.. (2021). Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Advances. 5(19). 3799–3806. 12 indexed citations
16.
Li, Zekun, Zhenping Chen, Guoqing Liu, et al.. (2021). Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Research and Practice in Thrombosis and Haemostasis. 5(5). e12562–e12562. 9 indexed citations
17.
18.
Li, Zekun, Zhenping Chen, Xiaoling Cheng, et al.. (2019). Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China. Research and Practice in Thrombosis and Haemostasis. 3(4). 741–748. 12 indexed citations
19.
Cheng, Xiaoling, et al.. (2017). Break‐through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A. Haemophilia. 24(1). 120–125. 3 indexed citations
20.
Cai, Jing, Tao Wang, Mingzhe Li, Xiaoling Cheng, & Yan Zhang. (2017). Isolated proteinuria in Chinese pregnant women with pre-eclampsia: Results of retrospective observational study. Biomedical Research-tokyo. 28(11). 5162–5166. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oliver Scherf‐Clavel Breakdown of academic impact, for papers by Manuel David Peris‐Díaz Breakdown of academic impact, for papers by Bart Hens Breakdown of academic impact, for papers by Uwe Thuß Breakdown of academic impact, for papers by Jean‐Paul Cano Breakdown of academic impact, for papers by J. D. Kruse-Jarres Breakdown of academic impact, for papers by Bonnie Mei-Wah Fong Breakdown of academic impact, for papers by Nelci F. Höehr Breakdown of academic impact, for papers by Xiaowen Yan Breakdown of academic impact, for papers by Alan Knapton
Rankless by CCL
2026